Real world data from lotus study evaluating long-term efficacy and tolerability outcomes of daybue® (trofinetide) in patients with rett syndrome published in developmental medicine and child neurology

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that the journal developmental medicine and child neurology published interim results from the caregiver-reported observational online, open-label, ongoing lotus study evaluating effectiveness and tolerability outcomes in patients with rett syndrome who are prescribed daybue® (trofinetide) under routine clinical care in the u.s. findings included reported improvements in symptoms of rett syndrome, with early.
ACAD Ratings Summary
ACAD Quant Ranking